Garcia-Mateo Sandra, Rondinella Debora, Ponziani Francesca Romana, Miele Luca, Gasbarrini Antonio, Cammarota Giovanni, Lanas Ángel, Gomollón Fernando
Department of Gastroenterology, "Lozano Blesa" Clinical Hospital, 50009, Zaragoza, Spain; Aragón Health Research Institute (IIS Aragón), 50009, Zaragoza, Spain; School of Medicine, University of Zaragoza, 50009, Zaragoza, Spain.
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Medical and Surgical Sciences, UOC Gastroenterologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Medical and Surgical Sciences, UOC CEMAD Centro Malattie dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.
Best Pract Res Clin Gastroenterol. 2024 Sep;72:101924. doi: 10.1016/j.bpg.2024.101924. Epub 2024 May 9.
Gut microbiota plays key functions in the human body, and its alteration is associated with several human disorders. Moreover, its manipulation is being investigated as a potential therapeutic strategy. In this narrative review we will dissect the involvement of the gut microbiota and of the gut-liver axis on metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, we will review the effects of lifestyle interventions commonly used for MASLD (i.e. Mediterranean diet and physical exercise) on gut microbiome, to understand if their beneficial effect can be microbially mediated. Finally, we will discuss the role and the available evidence of therapeutic microbiome modulators, including prebiotics, probiotics, symbiotics, and fecal microbiota transplantation (FMT), in the management of MASLD.
肠道微生物群在人体中发挥着关键作用,其改变与多种人类疾病相关。此外,对其进行调控正在作为一种潜在的治疗策略进行研究。在这篇叙述性综述中,我们将剖析肠道微生物群和肠-肝轴在代谢功能障碍相关脂肪性肝病(MASLD)中的作用。此外,我们将综述常用于MASLD的生活方式干预措施(即地中海饮食和体育锻炼)对肠道微生物组的影响,以了解它们的有益效果是否可通过微生物介导。最后,我们将讨论治疗性微生物组调节剂,包括益生元、益生菌、合生元和粪便微生物群移植(FMT)在MASLD管理中的作用及现有证据。